HEADER TRANSFERASE 12-NOV-19 6TEW TITLE CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA' (CSNK2A2 GENE TITLE 2 PRODUCT) IN COMPLEX WITH THE 2-AMINOTHIAZOLE-TYPE INHIBITOR 27 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA'; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II ALPHA'; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSNK2A2, CK2A2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEIN KINASE CK2, CASEIN KINASE 2, ATP-COMPETITIVE INHIBITOR, 2- KEYWDS 2 AMINOTHIAZOLE DERIVATIVE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR K.NIEFIND,D.LINDENBLATT,J.JOSE,V.M.APPLEGATE,A.NICKELSEN REVDAT 3 15-MAY-24 6TEW 1 REMARK REVDAT 2 05-AUG-20 6TEW 1 JRNL REMARK REVDAT 1 08-JUL-20 6TEW 0 JRNL AUTH D.LINDENBLATT,A.NICKELSEN,V.M.APPLEGATE,J.JOSE,K.NIEFIND JRNL TITL STRUCTURAL AND MECHANISTIC BASIS OF THE INHIBITORY POTENCY JRNL TITL 2 OF SELECTED 2-AMINOTHIAZOLE COMPOUNDS ON PROTEIN KINASE CK2. JRNL REF J.MED.CHEM. V. 63 7766 2020 JRNL REFN ISSN 0022-2623 JRNL PMID 32589844 JRNL DOI 10.1021/ACS.JMEDCHEM.0C00587 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.LINDENBLATT,A.NICKELSEN,V.M.APPLEGATE,J.HOCHSCHERF, REMARK 1 AUTH 2 B.WITULSKI,Z.BOUAZIZ,C.MARMINON,M.BRETNER,M.LE BORGNE, REMARK 1 AUTH 3 J.JOSE,K.NIEFIND REMARK 1 TITL DIACRITIC BINDING OF AN INDENOINDOLE INHIBITOR BY CK2A REMARK 1 TITL 2 PARALOGS EXPLORED BY A RELIABLE PATH TO ATOMIC RESOLUTION REMARK 1 TITL 3 CK2A' STRUCTURES. REMARK 1 REF ACS OMEGA V. 4 5471 2019 REMARK 1 REFN ESSN 2470-1343 REMARK 1 PMID 31559376 REMARK 1 DOI 10.1021/ACSOMEGA.8B03415 REMARK 2 REMARK 2 RESOLUTION. 1.08 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.17.1_3660 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.08 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 46.09 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.960 REMARK 3 COMPLETENESS FOR RANGE (%) : 61.2 REMARK 3 NUMBER OF REFLECTIONS : 106437 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.146 REMARK 3 R VALUE (WORKING SET) : 0.146 REMARK 3 FREE R VALUE : 0.169 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 1.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1066 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 46.0900 - 2.1300 0.98 20985 211 0.1323 0.1550 REMARK 3 2 2.1300 - 1.6900 0.97 20795 222 0.1365 0.1610 REMARK 3 3 1.6900 - 1.4800 0.96 20577 200 0.1477 0.1667 REMARK 3 4 1.4800 - 1.3400 0.94 20291 206 0.1929 0.2105 REMARK 3 5 1.3400 - 1.2500 0.66 14256 136 0.2310 0.2525 REMARK 3 6 1.2500 - 1.1700 0.26 5684 66 0.2419 0.2365 REMARK 3 7 1.1700 - 1.1100 0.10 2239 19 0.2451 0.2943 REMARK 3 8 1.1100 - 1.0700 0.03 544 6 0.2788 0.4400 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.077 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.054 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 12.70 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.15 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.014 2906 REMARK 3 ANGLE : 1.203 3927 REMARK 3 CHIRALITY : 0.102 403 REMARK 3 PLANARITY : 0.010 504 REMARK 3 DIHEDRAL : 15.432 1101 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6TEW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 12-NOV-19. REMARK 100 THE DEPOSITION ID IS D_1292105329. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-SEP-19 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PETRA III, EMBL C/O DESY REMARK 200 BEAMLINE : P13 (MX1) REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9202 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AUTOPROC REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 106454 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.082 REMARK 200 RESOLUTION RANGE LOW (A) : 46.094 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 64.0 REMARK 200 DATA REDUNDANCY : 6.900 REMARK 200 R MERGE (I) : 0.06300 REMARK 200 R SYM (I) : 0.06300 REMARK 200 FOR THE DATA SET : 12.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.08 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.21 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 1.58500 REMARK 200 R SYM FOR SHELL (I) : 1.58500 REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: AB INITIO PHASING REMARK 200 SOFTWARE USED: ARCIMBOLDO REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.59 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.35 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: RESERVOIR COMPOSITION: 28 % (W/V) REMARK 280 PEG6000, 0.9 M LICL, 0.1 M, TRIS/HCL, PH 8.5; CRYSTALLIZATION REMARK 280 DROP COMPOSITION PRIOR TO EQUILIBRATION: 0.01 ML RESERVOIR REMARK 280 SOLUTION PLUS 0.02 ML CK2ALPHA' (MUTANT CYS336SER)/INHIBITOR REMARK 280 MB002 MIXTURE (0.180 ML 6 MG/ML CK2ALPHA-'CYS336SER, 0.5 M NACL, REMARK 280 25 MM TRIS/HCL, PH 8.5, MIXED AND PRE-EQUILIBRATED WITH 0.02 ML REMARK 280 10 MM MB002 IN DIMETHYL SULFOXIDE); THE INHIBITOR MB002 WAS REMARK 280 REPLACED BY EXTENSIVE SOAKING WITH THE 2-AMINOTHIAZOLE-TYPE REMARK 280 INHIBITOR 27; VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 390 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 14870 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 6.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -13 REMARK 465 GLY A -12 REMARK 465 SER A -11 REMARK 465 SER A -10 REMARK 465 HIS A -9 REMARK 465 HIS A -8 REMARK 465 HIS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 HIS A -4 REMARK 465 SER A -3 REMARK 465 GLN A -2 REMARK 465 ASP A -1 REMARK 465 PRO A 0 REMARK 465 MET A 1 REMARK 465 PRO A 2 REMARK 465 GLY A 3 REMARK 465 PRO A 4 REMARK 465 ALA A 5 REMARK 465 ALA A 6 REMARK 465 GLY A 7 REMARK 465 SER A 333 REMARK 465 GLN A 334 REMARK 465 PRO A 335 REMARK 465 SER A 336 REMARK 465 ALA A 337 REMARK 465 ASP A 338 REMARK 465 ASN A 339 REMARK 465 ALA A 340 REMARK 465 VAL A 341 REMARK 465 LEU A 342 REMARK 465 SER A 343 REMARK 465 SER A 344 REMARK 465 GLY A 345 REMARK 465 LEU A 346 REMARK 465 THR A 347 REMARK 465 ALA A 348 REMARK 465 ALA A 349 REMARK 465 ARG A 350 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 157 45.44 -148.56 REMARK 500 ASP A 176 75.16 58.49 REMARK 500 ALA A 194 155.34 67.84 REMARK 500 MET A 209 52.76 -93.90 REMARK 500 HIS A 235 71.47 -103.71 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue N5Q A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 403 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 6TE2 RELATED DB: PDB REMARK 900 6TE2 CONTAINS A DIFFERENT 2-AMINOTHIAZOLE-TYPE INHIBITOR. DBREF 6TEW A 1 350 UNP P19784 CSK22_HUMAN 1 350 SEQADV 6TEW MET A -13 UNP P19784 INITIATING METHIONINE SEQADV 6TEW GLY A -12 UNP P19784 EXPRESSION TAG SEQADV 6TEW SER A -11 UNP P19784 EXPRESSION TAG SEQADV 6TEW SER A -10 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -9 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -8 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -7 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -6 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -5 UNP P19784 EXPRESSION TAG SEQADV 6TEW HIS A -4 UNP P19784 EXPRESSION TAG SEQADV 6TEW SER A -3 UNP P19784 EXPRESSION TAG SEQADV 6TEW GLN A -2 UNP P19784 EXPRESSION TAG SEQADV 6TEW ASP A -1 UNP P19784 EXPRESSION TAG SEQADV 6TEW PRO A 0 UNP P19784 EXPRESSION TAG SEQADV 6TEW SER A 336 UNP P19784 CYS 336 ENGINEERED MUTATION SEQRES 1 A 364 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER GLN ASP SEQRES 2 A 364 PRO MET PRO GLY PRO ALA ALA GLY SER ARG ALA ARG VAL SEQRES 3 A 364 TYR ALA GLU VAL ASN SER LEU ARG SER ARG GLU TYR TRP SEQRES 4 A 364 ASP TYR GLU ALA HIS VAL PRO SER TRP GLY ASN GLN ASP SEQRES 5 A 364 ASP TYR GLN LEU VAL ARG LYS LEU GLY ARG GLY LYS TYR SEQRES 6 A 364 SER GLU VAL PHE GLU ALA ILE ASN ILE THR ASN ASN GLU SEQRES 7 A 364 ARG VAL VAL VAL LYS ILE LEU LYS PRO VAL LYS LYS LYS SEQRES 8 A 364 LYS ILE LYS ARG GLU VAL LYS ILE LEU GLU ASN LEU ARG SEQRES 9 A 364 GLY GLY THR ASN ILE ILE LYS LEU ILE ASP THR VAL LYS SEQRES 10 A 364 ASP PRO VAL SER LYS THR PRO ALA LEU VAL PHE GLU TYR SEQRES 11 A 364 ILE ASN ASN THR ASP PHE LYS GLN LEU TYR GLN ILE LEU SEQRES 12 A 364 THR ASP PHE ASP ILE ARG PHE TYR MET TYR GLU LEU LEU SEQRES 13 A 364 LYS ALA LEU ASP TYR CYS HIS SER LYS GLY ILE MET HIS SEQRES 14 A 364 ARG ASP VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLN SEQRES 15 A 364 GLN LYS LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU SEQRES 16 A 364 PHE TYR HIS PRO ALA GLN GLU TYR ASN VAL ARG VAL ALA SEQRES 17 A 364 SER ARG TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP TYR SEQRES 18 A 364 GLN MET TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY SEQRES 19 A 364 CYS MET LEU ALA SER MET ILE PHE ARG ARG GLU PRO PHE SEQRES 20 A 364 PHE HIS GLY GLN ASP ASN TYR ASP GLN LEU VAL ARG ILE SEQRES 21 A 364 ALA LYS VAL LEU GLY THR GLU GLU LEU TYR GLY TYR LEU SEQRES 22 A 364 LYS LYS TYR HIS ILE ASP LEU ASP PRO HIS PHE ASN ASP SEQRES 23 A 364 ILE LEU GLY GLN HIS SER ARG LYS ARG TRP GLU ASN PHE SEQRES 24 A 364 ILE HIS SER GLU ASN ARG HIS LEU VAL SER PRO GLU ALA SEQRES 25 A 364 LEU ASP LEU LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SEQRES 26 A 364 GLN ARG LEU THR ALA LYS GLU ALA MET GLU HIS PRO TYR SEQRES 27 A 364 PHE TYR PRO VAL VAL LYS GLU GLN SER GLN PRO SER ALA SEQRES 28 A 364 ASP ASN ALA VAL LEU SER SER GLY LEU THR ALA ALA ARG HET N5Q A 401 39 HET EDO A 402 10 HET EDO A 403 10 HETNAM N5Q 4-[(4-NAPHTHALEN-2-YL-1,3-THIAZOL-2-YL)AMINO]-2- HETNAM 2 N5Q OXIDANYL-BENZOIC ACID HETNAM EDO 1,2-ETHANEDIOL HETSYN EDO ETHYLENE GLYCOL FORMUL 2 N5Q C20 H14 N2 O3 S FORMUL 3 EDO 2(C2 H6 O2) FORMUL 5 HOH *253(H2 O) HELIX 1 AA1 SER A 21 ASP A 26 1 6 HELIX 2 AA2 TYR A 27 HIS A 30 5 4 HELIX 3 AA3 LYS A 75 LEU A 89 1 15 HELIX 4 AA4 ASP A 121 TYR A 126 1 6 HELIX 5 AA5 THR A 130 LYS A 151 1 22 HELIX 6 AA6 LYS A 159 HIS A 161 5 3 HELIX 7 AA7 SER A 195 LYS A 199 5 5 HELIX 8 AA8 GLY A 200 VAL A 205 1 6 HELIX 9 AA9 TYR A 212 ARG A 229 1 18 HELIX 10 AB1 ASP A 238 GLY A 251 1 14 HELIX 11 AB2 GLY A 251 HIS A 263 1 13 HELIX 12 AB3 ASP A 267 ILE A 273 5 7 HELIX 13 AB4 ARG A 281 ILE A 286 5 6 HELIX 14 AB5 ASN A 290 VAL A 294 5 5 HELIX 15 AB6 SER A 295 LEU A 306 1 12 HELIX 16 AB7 THR A 315 HIS A 322 1 8 HELIX 17 AB8 PHE A 325 GLN A 332 1 8 SHEET 1 AA1 6 GLY A 35 ASN A 36 0 SHEET 2 AA1 6 LEU A 98 LYS A 103 1 O THR A 101 N GLY A 35 SHEET 3 AA1 6 PRO A 110 GLU A 115 -1 O VAL A 113 N ASP A 100 SHEET 4 AA1 6 ARG A 65 LEU A 71 -1 N VAL A 67 O PHE A 114 SHEET 5 AA1 6 SER A 52 ASN A 59 -1 N PHE A 55 O VAL A 68 SHEET 6 AA1 6 TYR A 40 ARG A 48 -1 N GLN A 41 O ILE A 58 SHEET 1 AA2 2 ILE A 153 MET A 154 0 SHEET 2 AA2 2 GLU A 181 PHE A 182 -1 O GLU A 181 N MET A 154 SHEET 1 AA3 2 VAL A 163 ASP A 166 0 SHEET 2 AA3 2 LYS A 171 LEU A 174 -1 O LYS A 171 N ASP A 166 CISPEP 1 GLU A 231 PRO A 232 0 -8.04 SITE 1 AC1 15 LEU A 46 GLY A 47 ARG A 48 VAL A 54 SITE 2 AC1 15 VAL A 67 LYS A 69 PHE A 114 ILE A 117 SITE 3 AC1 15 ASN A 119 HIS A 161 MET A 164 ILE A 175 SITE 4 AC1 15 ASP A 176 HOH A 565 HOH A 638 SITE 1 AC2 5 PHE A 55 LYS A 304 GLU A 318 HOH A 519 SITE 2 AC2 5 HOH A 569 SITE 1 AC3 4 PHE A 132 ASP A 133 PHE A 136 LYS A 170 CRYST1 46.108 47.380 50.270 113.55 90.29 91.19 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021688 0.000449 0.000313 0.00000 SCALE2 0.000000 0.021110 0.009206 0.00000 SCALE3 0.000000 0.000000 0.021702 0.00000